Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab to Induce ER Expression in Breast Cancer
NCT00726180Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2008
- Primary completion
- Jun 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by University of Michigan Rogel Cancer Center. Started Jul 2008; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00726180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726180.